Belite Bio, Inc

Belite Bio, Inc is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for age-related macular degeneration and liver diseases. Its lead product candidate, LBS-008, is an oral once-a-day treatment in phase 3 clinical trial, targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy for liver diseases, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, currently in preclinical development.

Products

• LBS-008 - Oral once-a-day treatment for atrophic age-related macular degeneration and autosomal recessive stargardt diseases

• LBS-009 - Anti-retinol binding protein 4 oral therapy for liver diseases